More than 35 Abstracts Demonstrate the Value of the nCounter Platform for Targeted Discovery,
NanoString's New Digital Spatial Profiling Technology Featured in Two Abstracts
"The breadth of nCounter-based research at this year's ASCO conference demonstrates the scientific momentum and significant
commercial advances that we've made in our key markets, most notably immuno-oncology," said
More than 35 abstracts will be presented at the ASCO Annual Meeting, which is being held
Multidimensional spatial characterization of the tumor microenvironment (TME) in synchronous melanoma metastases (SMM) to yield insights into mixed responses to therapy in metastatic melanoma (MM) patients (pts). (Abstract # 9575)
NanoString's new Digital Spatial Profiling research platform was used for spatial characterization of 30 immune markers and signaling proteins in melanoma patient samples to understand correlations and determinants of response.
Molecular characterization of immune-related severe adverse events (irSAE). (Abstract #3076)
NanoString Digital Spatial Profiling was used to profile the immune cell population in tissue affected by immune checkpoint inhibitors-mediated inflammation. Similarities and differences between autoimmune disease and colon-irSAEs were identified at the gene expression and proteomic levels, as regions of inflammation showed higher CD68 and PD-L1 positivity in colon-irSAE specimens versus normal colon or Crohn's specimens, and reduced beta-catenin levels in both Crohn's and colon-irSAE specimens relative to normal controls.
Distinct gene expression, mutational profile and clinical outcomes of V600E and V600K/R BRAF-mutant metastatic melanoma (MM). (Abstract #9541)
Gene expression and mutational profiling were used to investigate potential mechanisms explaining the observation that V600K/R metastatic melanoma has inferior response and shorter survival with MAPKi than V600E.
Correlation of constitutive PD-1 resistance in HNC with GM-CSF expression and presence of myeloid derived suppressor cells (MDSCs). (Abstract #6049)
A 638-gene immune gene expression panel was used to explore why the majority of INF-G inflamed head and neck squamous cell carcinomas (HNC) tumors do not respond to PD-1 checkpoint blockade. Constitutive resistance to PD-1 checkpoint blockade in inflamed HNC associates with expression of GM-CSF and Myeloid Derived Suppressor Cell (MDSC) markers. Strategies to deplete MDSCs, such as chemotherapy, should be considered in combination or sequentially with anti-PD-1.
Cellular immune biomarkers to prognosticate for survival to adoptive T-cell therapy in advanced nasopharyngeal cancer. (Abstract
nCounter platform and reagents were used for longitudinal modular transcriptome analysis of PBMC from patients with stage 4c nasopharyngeal carcinoma who received first line chemo-immunotherapy with the aim of identifying signatures associated with positive clinical outcomes.
Results from this study showed that 2-year survivors displayed significant decreased amounts of monocytic myeloid-derived suppressor cells (mMDSCs), compared to non-survivors.
Phase II study of durvalumab (anti-PD-L1 antibody) in combination with R-CHOP or lenalidomide plus R-CHOP in previously untreated, high-risk diffuse large B-cell lymphoma. (Abstract # TPS7573)
NanoString's Lymphoma Subtyping Test is being used to determine Cell of Origin in an ongoing clinical trial. The primary study objective is to explore the clinical activity of durvalumab with R-CHOP in non-activated B-cell-like (non-
Association of molecular subtype, proliferation, and immune genes with efficacy of carboplatin versus gemcitabine addition to taxane-based, anthracycline-free neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC): Results of the randomized WSG ADAPT-TN trial. (Abstract #573)
Impact of consensus molecular subtyping (CMS) on overall survival (OS) and progression free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance). (Abstract #3511)
CALGB 80405 was a randomized Ph3 trial showing no OS or PFS difference in mCRC pts treated with Bevacizumab (Bev) or Cetuximab (Cet) in the first line. A
Impact of the Prosigna (PAM50) assay on adjuvant clinical decision making in patients with early stage breast cancer: Results of a prospective multicenter public program. (Abstract # e12062)
In this prospective decision impact study, Prosigna results led to a 39% change in adjuvant therapy indication. Patients with initial indication of CHT were changed to HT alone in > 50% of cases. Thus, Prosigna results influenced the treatment decisions and reinforced its clinical utility in real-world settings. The intrinsic subtype classification based on IHC didn't show to be an adequate surrogate for the genomic subtypes as determined by Prosigna.
At the 2017 ASCO Annual Meeting,
|e23198||Molecular classification with
|e23103||Molecular sequencing and gene fusion detection in non-small cell lung cancer (NSCLC) patients: |
Impact of co-existing alterations.
|3076||Molecular characterization of immune-related severe adverse events (irSAE).||http://abstracts.asco.org/199/AbstView_199_193474.html|
|8015||Pembrolizumab (Pembro) plus lenalidomide (Len) and low-dose dexamethasone (Dex) |
for relapsed/refractory multiple myeloma (RRMM): Efficacy and biomarker analyses.
|e21030||Immune cell profiling of melanoma metastases from patients treated with TriMixDC-MEL |
dendritic cell therapy in combination with ipilimumab.
|3509||Clinical utility of colon cancer molecular subtypes: Validation of two main colorectal molecular |
classifications on the PETACC-8 phase III trial cohort.
|530||Effects of age, immune landscape, and response to trastuzumab (H) in HER-2 positive (HER2+) |
breast cancer in NCCTG (Alliance)-N9831.
|TPS7573||Phase II study of durvalumab (anti-PD-L1 antibody) in combination with R-CHOP or lenalidomide |
plus R-CHOP in previously untreated, high-risk diffuse large B-cell lymphoma.
|E12062||Impact of the Prosigna (PAM50) assay on adjuvant clinical decision making in patients with early |
stage breast cancer: Results of a prospective multicenter public program.
|7512||Clinical and biologic covariates of outcomes in ZUMA-1: A pivotal trial of axicabtagene ciloleucel |
(axi-cel; KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma (r-NHL).
|9575||Multidimensional spatial characterization of the tumor microenvironment (TME) in synchronous |
melanoma metastases (SMM) to yield insights into mixed responses to therapy in metastatic melanoma
(MM) patients (pts).
|e14614||Intra-tumour heterogeneity in the regulation of immune-tolerogenic pathways in primary and metastatic |
hepatocellular carcinoma (HCC).
|e13052||Molecular profiling of cancer outliers.||
|e12134||Immune biomarkers and treatment (tx) outcome in hormone receptor-positive (HR+) breast cancer |
(BC) patients (pts) treated with preoperative chemotherapy (preop chemo) plus bevacizumab (bev).
|3511||Impact of consensus molecular subtyping (CMS) on overall survival (OS) and progression free survival |
(PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405
|e12134||Different patterns of non immediate allergic reaction to BRAF inhibitor in two patients with metastatic |
|e20028||Novel prognostic markers for epithelioid malignant pleural mesothelioma.||http://abstracts.asco.org/199/AbstView_199_191936.html|
|e21052||Different patterns of non immediate allergic reaction to BRAF inhibitor in two patients with metastatic |
|e23091||Effect of bavituximab in combination with nivolumab on tumor immune response in a 3D ex vivo |
system of lung cancer patients.
|7547||Rapid, real-time central pathology review for E1412: A novel and successful paradigm for future |
National Clinical Trials Network diffuse large B cell lymphoma studies.
|e20050||Prognostic gene signatures for lung adenocarcinoma using digital multiplexed gene expression in |
formalin-fixed paraffin embedded tissue.
|9541||Distinct gene expression, mutational profile and clinical outcomes of V600E and V600K/R BRAF-mutant |
metastatic melanoma (MM).
|5591||High-intermediate risk endometrial cancer: Can gene expression predict recurrence?||http://abstracts.asco.org/199/AbstView_199_194796.html|
|6047||Cellular immune biomarkers to prognosticate for survival to adoptive T-cell
therapy in advanced |
|e12541||Identification of differentially expressed genes associated with clinical response after treatment of |
breast cancer skin metastases with imiquimod.
|10503||Molecular alterations to predict survival and response to chemotherapy of pediatric low-grade glioma.||http://abstracts.asco.org/199/AbstView_199_188674.html|
|e23090||Anti-PD1 treatment to induce M1 polarization of tumor infiltrating macrophages in a 3D ex vivo system |
of lung cancer patients.
|8557||Biomarkers of pembrolizumab (P) activity in mesothelioma (MM): Results from a phase II trial.||http://abstracts.asco.org/199/AbstView_199_191066.html|
|6049||Correlation of constitutive PD-1 resistance in HNC with GM-CSF expression and presence of myeloid |
derived suppressor cells (MDSCs).
|511||Seven-year (yr) follow-up of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, |
HER2-positive breast cancer (BC).
|529||Impact of DNA repair deficiency signature on outcomes in triple negative breast cancer (TNBC) patients |
treated with AC chemotherapy (SWOG S9313).
|e20610||Coexistence of rearranged during transfection (RET) variants and activating EGFR mutations with their |
molecular implications in lung adenocarcinomas.
|e23205||In silico validation of a prostate cancer recurrence prognostic signature based on pathways related to |
|e13090||Characterization of germline and tumor genomic profile in unselected young black breast cancer patients.||http://abstracts.asco.org/199/AbstView_199_189758.html|
|8573||Pembrolizumab in patients with recurrent thymic carcinoma: Results of a phase II study.||http://abstracts.asco.org/199/AbstView_199_191168.html|
|TPS594||CORALLEEN: A phase 2 clinical trial of chemotherapy or letrozole plus ribociclib as neoadjuvant treatment |
for postmenopausal patients with luminal B/HER2-negative breast cancer.
|11553||CCL5 expression and tumor infiltrating immune cells in triple negative breast cancer.||http://abstracts.asco.org/199/AbstView_199_190711.html|
|573||Association of molecular subtype, proliferation, and immune genes with efficacy of carboplatin versus |
gemcitabine addition to taxane-based, anthracycline-free neoadjuvant chemotherapy in early triple-negative
breast cancer (TNBC): Results of the randomized WSG ADAPT-TN trial.
About NanoString Technologies, Inc.
For more information, please visit www.nanostring.com.
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding the capabilities of the company's products. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes
and results to differ materially. These risks and uncertainties, many of which are beyond our control, include market acceptance of our products; the impact of competition; as well as the other risks set forth in the company's filings with the
Doug FarrellVice President, Investor Relations & Corporate Communications email@example.com Phone: 206-602-1768
News Provided by Acquire Media